Test Price
2,800 AED✅ Home Collection Available
CLN3 Gene Neuronal Ceroid Lipofuscinosis Type 3 Genetic Test – UAE | DNA Labs UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO‑certified NGS processing with independent validation.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
- Post‑Test Telephonic Guidance – Clinical interpretation of results by our Consultant Medical Genetics.
- Direct Insurance Billing – Verify via WhatsApp +971 54 548 8731.
Our laboratory delivers a definitive molecular diagnosis for juvenile‑onset Batten disease with the most comprehensive NGS‑based CLN3 gene assay in the UAE, accredited under DHA Facility License 1143.
DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) test screens the entire coding region of the CLN3 gene for pathogenic variants causing juvenile‑onset neuronal ceroid lipofuscinosis (Batten disease). It is the most comprehensive genetic assay available in the UAE, delivering a definitive molecular diagnosis in 3–4 weeks.
| Feature | DNA Labs UAE Test | Typical Alternative |
|---|---|---|
| Precision | >99.9% analytical sensitivity & specificity (NGS) | ~95–98% (Sanger sequencing or limited panels) |
| Method | Next‑Generation Sequencing (full gene coverage, CNV analysis) | Single‑exon sequencing; may miss deep intronic or structural variants |
| Turnaround Time | 3–4 Weeks (expedited option available) | 6–8 Weeks (overseas labs) |
| UAE Accreditation | ISO‑certified, DHA‑licensed (License 1143) | Often unaccredited foreign processing |
Physician Insight & Safety Protocols
“This genetic test is a pivotal step for families navigating the diagnostic odyssey of Batten disease. The results provide clarity but must be delivered with compassion and expert counselling. I emphasise that no clinical decisions should be made without a thorough post‑test consultation with a qualified genetic specialist.”
Lina Osama Zaki Quteineh — Consultant Medical Genetics | DHA Registration ID: 9294403
⚠️ Medication Warning: Do not discontinue any prescribed medication or treatment without explicit instruction from your treating physician. A genetic test result does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active febrile illness, severe anaemia, uncorrected coagulopathy, or inability to provide informed consent (for paediatric patients, legal guardian consent is mandatory per Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Post‑Venipuncture Alert: If you experience excessive bleeding, fainting, or signs of infection at the draw site (redness, swelling, pus), seek immediate medical attention.
- Psychological Distress: Genetic results may provoke severe emotional reactions. Urgent psychological support should be accessed via your referring physician.
Patient FAQ & Clinical Guidance
1. What exactly does the CLN3 Gene NGS Test look for?
This test uses Next‑Generation Sequencing to identify all pathogenic mutations in the CLN3 gene associated with Juvenile Batten disease (neuronal ceroid lipofuscinosis type 3). It covers the entire coding region and detects copy number variants.
2. How long will it take to receive my results?
Standard reporting time is 3 to 4 weeks from sample arrival; expedited processing can be arranged for urgent cases.
3. Do I need any special preparation before the blood draw?
No fasting or medication changes are needed; simply provide your detailed medical history and complete the informed consent form.
4. Can I have the sample collected at home?
Yes, our VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection service is available daily from 8 AM to 11 PM for standard peripheral blood specimens.
5. Will my insurance cover the test?
We offer direct insurance billing for many providers. Please contact us via WhatsApp at +971 54 548 8731 to verify your coverage.
UAE Regulatory & Data Privacy Adherence
This laboratory strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for genomic data confidentiality, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for secure health information exchange. All clinical safety and patient consent procedures comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our facility is DHA‑licensed under License 1143 and audited under ISO 9001:2015 standards.
Clinical & Logistical Metadata
| Test Name | CLN3 Gene Neuronal Ceroid Lipofuscinosis Type 3 (Batten Disease) NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (expedited option available) |
| Sample Type / Matrix | Peripheral Whole Blood (3 mL in EDTA tube) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Whole gene coverage with CNV analysis |
| ICD‑10‑CM Code | E75.4 (Neuronal ceroid lipofuscinosis) |
| LOINC Code | 82329-8 (CLN3 gene full sequencing) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians